Lead Investigator: Zisheng Chen, Guangzhou Medical University
Title of Proposal Research: The Association between Liver Metastasis of Non-Small Cell Lung Cancer and Prognosis Based on Immunotherapy: A Secondary Summary analysis of Individual Patient Data from Randomized Trials
Vivli Data Request: 10707
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Lung cancer is a serious disease that affects many people around the world. When lung cancer spreads to the liver, the chances of survival are very low, with most patients living only about three months after diagnosis. This is a big concern, as lung cancer is one of the most common types of cancer and impacts thousands of individuals and their families each year.
Recent studies show that combining chemotherapy, which uses strong drugs to kill cancer cells, with immunotherapy, which helps the body’s immune system fight cancer, can lead to better results for patients with lung cancer that has spread to the liver. However, we still have questions. For example, we don’t know if adding extra immunotherapy for patients with liver metastases (cancer spread) is better than for those without. We also need to find out which patients with liver metastases will benefit the most from treatment and when immunotherapy should be given and discontinued.
Our research aims to answer these important questions. We want to understand which patients with lung cancer and liver metastases will get the best results from treatment and the best timing for immunotherapy. By figuring this out, we hope to improve treatment plans and patient care.
To conduct our research, we will look closely at data from past clinical trials that involved patients with lung cancer that has spread to the liver. We will compare outcomes for different treatment combinations, including chemotherapy alone and the combination of chemotherapy and immunotherapy. By analyzing these results, we hope to identify patterns that can help doctors choose the most effective treatments.
This research is important because it will help improve the understanding of how to treat lung cancer that has spread to the liver. Our findings could lead to better survival rates and a higher quality of life for those affected by this challenging condition.
Requested Studies:
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
Data Contributor: AstraZeneca
Study ID: NCT02453282
Sponsor ID: D419AC00001
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
Data Contributor: AstraZeneca
Study ID: NCT02542293
Sponsor ID: D419AC00003
A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02409342
Sponsor ID: GO29431
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02366143
Sponsor ID: GO29436
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02367794
Sponsor ID: GO29437
A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02367781
Sponsor ID: GO29537
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02657434
Sponsor ID: GO29438